Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Q-linea AB's average Book Value per Share Growth Rate was -22.90% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -71.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Q-linea AB was 501.00% per year. The lowest was -71.10% per year. And the median was -20.50% per year.
Q-linea AB (CHIX:QLINEs) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Q-linea AB 3-Year Book Growth Rate Related Terms
CHIX:QLINES vs ABT, SYK, MDT: 3-Year Book Growth Rate Comparison
For the Medical Devices subindustry, Q-linea AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Q-linea AB's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -71.10% mean?
Q-linea AB (CHIX:QLINES) has a 3-Year Book Growth Rate of -71.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #741 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 97.9%.
Is Q-linea AB's 3-Year Book Growth Rate too high?
Q-linea AB's current 3-Year Book Growth Rate is -71.10%. Based on the distribution chart, Q-linea AB ranks #741 out of 757 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's 3-Year Book Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #741 out of 757 companies for 3-Year Book Growth Rate. This places Q-linea AB in the lower half of its industry. The industry median 3-Year Book Growth Rate is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.30, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current 3-Year Book Growth Rate is -71.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current 3-Year Book Growth Rate of -71.10%. The stock's GF Value™ is kr1,639.51, compared to a current price of kr1,610.00 — trading 1.8% below its estimated fair value. The current 3-Year Book Growth Rate is -71.10%. Q-linea AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current 3-Year Book Growth Rate is -71.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 1.8% below its estimated GF Value™ of kr1,639.51.
Key valuation signals for CHIX:QLINES:
3-Year Book Growth Rate: -71.10%
GF Value™: kr1,639.51 vs. price of kr1,610.00 (1.8% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
66GF Score
Get the complete analysis for CHIX:QLINES
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
